Everolimus (RAD001) in Breast Cancer—The BOLERO Program
What is the BOLERO clinical trial Program? Novartis has initiated the BOLERO (Breast cancer trials of OraLEveROlimus) clinical trial program to evaluate everolimus (RAD001) in recurrent, locally-advanced, or metastatic breast cancer.
Currently, the BOLERO clinical trial program comprises:
BOLERO-1 (To find out more about this breast cancer clinical trial, click here)
BOLERO-2 (To find out more about this breast cancer clinical trial, click here)
BOLERO-3 (To find out more about this breast cancer clinical trial, click here)
Disclaimer : These are investigational studies; there is no guarantee that everolimus will become commercially available for these indications
Disclaimer : This is an international web site for the The WIDE Program™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain information that is different from where you practice. Please contact your local Novartis Medical Scientific Liaison for the latest information specific to your country.
BOLERO-1 (To find out more about this breast cancer clinical trial,